CGTX Earnings Date: Nov 5, 2026 (Estimated) — Cognition Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is CGTX's next earnings date?
Cognition Therapeutics, Inc. (CGTX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.07 on revenue of $5.3M.
How did CGTX do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Cognition Therapeutics, Inc. posted EPS of -$0.04 versus the -$0.06 estimate, a beat of 33.3%. Revenue was $0 against a $5.0M estimate. The stock's 1-day post-earnings move was -4.4%.
How much does CGTX stock move after earnings?
CGTX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a biopharmaceutical company in the clinical stage, focused on identifying and advancing small molecule treatments. The firm's research and development efforts are primarily directed towards age-related neurodegenerative conditions affecting the central nervous system, as well as retinal disorders. Its most advanced experimental therapy is CT1812, which acts as a sigma-2 receptor antagonist. This compound is currently being evaluated in Phase II clinical trials for the management of mild-to-moderate Alzheimer's disease and dementia with Lewy bodies (DLB). Additionally, it has successfully concluded Phase I trials for early-stage Alzheimer's and is undergoing preclinical investigation for dry age-related macular degeneration (AMD). The company's pipeline also includes CT2168, a treatment candidate for synucleinopathies—a category of diseases encompassing DLB and Parkinson's disease—and CT2074, which is in development for dry AMD. Cognition Therapeutics, Inc. was established in 2007 and operates from its headquarters in Purchase, New York.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.06 | -0.04 | +33.33% | $0 | ✅ Beat | -4.42% | -7.96% | -8.85% |
| 2026-05-19 | Q1 2026 | -0.07 | -0.05 | +28.57% | $0 | ✅ Beat | +16.22% | +7.21% | +30.63% |
| 2026-03-26 | Q4 2025 | -0.07 | -0.01 | +85.71% | $0 | ✅ Beat | -2.70% | -19.69% | +15.32% |
| 2025-11-06 | Q3 2025 | -0.08 | -0.06 | +25.00% | $0 | ✅ Beat | -1.78% | +1.78% | +2.37% |
| 2025-03-20 | Q4 2024 | -0.15 | -0.17 | -13.33% | $0 | ❌ Miss | -5.18% | -1.87% | -17.24% |
| 2024-11-13 | Q3 2024 | -0.22 | -0.25 | -13.64% | $0 | ❌ Miss | -10.24% | -25.80% | -15.01% |
| 2024-05-07 | Q1 2024 | -0.29 | -0.27 | +6.90% | $0 | ✅ Beat | -3.52% | -2.01% | -4.52% |
| 2024-03-26 | Q4 2023 | -0.34 | -0.27 | — | $0 | ✅ Beat | +0.55% | -0.55% | +9.34% |
Showing last 8 quarters.